GlassScriptPhysician profile
Moustafa Alamy
NPI 1184659161
$6,632.86
in general payments reported to CMS, 2019-2025
14 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $798 · 2021: $869 · 2022: $973 · 2023: $861 · 2024: $936 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.67 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,524.48 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $1,500.26 | 2019-2025 | Livdelzi |
| Ardelyx, INC. | $1,192.41 | 2022-2025 | Ibsrela |
| Abbvie INC. | $773.57 | 2019-2025 | Viberzi, Linzess, Mavyret |
| Madrigal Pharmaceuticals | $725.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $223.74 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $216.02 | 2019-2023 | Linzess |
| Redhill Biopharma INC. | $173.50 | 2020-2024 | Talicia |
| Takeda Pharmaceuticals U.S.A., INC. | $135.54 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $95.21 | 2020-2023 | Ocaliva |
| Erbe USA INC | $20.40 | 2019 | |
| Cook Medical LLC | $18.43 | 2019 | |
| Boston Scientific Corporation | $17.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moustafa Alamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.